From: Imaging endpoints for clinical trials in Alzheimer’s disease
Compound | Subject numbers | Follow-up duration (months) | Treatment effect | |
---|---|---|---|---|
Placebo arm | Treatment arm | |||
AN-1792 [35] | 57 | 231a | 11 | Ventricles (⇑), whole brain atrophy (⇑, antibody responders only), hippocampus (⇔) |
Atorvastatin and donepezil [38] | 64b | 18 | Whole brain (⇔), hippocampus (⇓) | |
Bapineuzumab (phase II) [21] | 122 | 107 | 18 | Whole brain (⇓, in ε4 noncarriers)c, ventricles (⇑, in ε4 carriers)d |
Bapineuzumab (phase III) ε4 carriers [22] | 238 | 352 | 18 | Whole brain (⇔) |
Bapineuzumab (phase III) ε4 noncarriers [22] | 244 | 315e | 18 | Whole brain (⇔) |
CAD106 [19] | 7/5 | 24/21f | 6, 12 | Whole brain (⇔)g, ventricles (⇔), hippocampus (⇓)h |
Docosahexaenoic acid [33] | 49 | 53 | 18 | Whole brain (⇔), ventricles (⇔), hippocampus (⇔) |
Intravenous immunoglobulin [32] | 7 | 21 | 3, 6 | Whole brain (⇔), hippocampus (⇔) |
Memantine [40] | 40i | 12 | Whole brain (⇔), ventricles (⇔), hippocampus(⇓, right only) | |
Memantine [41] | 118 | 110 | 12 | Whole brain (⇔), hippocampus (⇔) |
Rosiglitazone [34] | 38 | 38 | 6, 12 | Whole brain (⇔) |
Scyllo-inositol [31] | 83 | 259 | 18 | Whole brain (⇔), ventricles (⇑), hippocampi (⇔) |
Semagacestat [30] | 208b | 18 | Whole brain (⇔), hippocampus (⇔) | |
Solaneuzumab [29] | 370/400j | 370/406 | 18 | Whole brain (⇔), hippocampus (⇔) |
109 | 203k | 18 | Hippocampus (⇓)l |